{rfName}
Ph

Indexed in

License and use

Citations

1

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Garcia, YAuthorBarretina-Ginesta, PAuthorGil-Martin, MAuthorRomeo, MAuthor

Share

September 23, 2015
Publications
>
Meeting Abstract
No

Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL).

Publicated to:Journal Of Clinical Oncology. 33 (15): 5531-5531 - 2015-05-20 33(15), DOI: 10.1200/jco.2015.33.15_suppl.5531

Authors: García, Y; De Juan, A; Mendiola, C; Barretina-Ginesta, P; Vidal, L; Santaballa, A; Bover, I; Gil-Martin, M; Manzano, A; Rubio, MJ; Romeo, M; de Liaño, AG; García-Martínez, E; Gonzalez-Martin, A

Affiliations

- Author
GEICO, Madrid, Spain - Author
GEICO, Palma De Mallorca, Spain - Author
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Serv Oncol Med, Badalona, Spain - Author
Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain - Author
Hosp Gen Univ Morales Meseguer, GEICO, Murcia, Spain - Author
Hosp Marques Valdecilla, Santander, Spain - Author
Hosp Reina, Cordoba, Spain - Author
Hosp Son Llatzer, Palma De Mallorca, Spain - Author
Hosp Univ & Politecn La Fe, Valencia, Spain - Author
Hosp Univ 12 Octubre, Madrid, Spain - Author
Hosp Univ Clin San Carlos, Madrid, Spain - Author
Hosp Univ Josep Trueta, Inst Catala Oncol, Dept Med Oncol, Girona, Spain - Author
Inst Catala Oncol, Early Clin Res Unit, Barcelona, Spain - Author
MD Anderson Canc Ctr Spain, Madrid, Spain - Author
Univ Autonoma Barcelona, Corp Sanitaria Univ Parc Tauli, E-08193 Barcelona, Spain - Author
See more

Abstract

Keywords

Good health and well-being

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of Clinical Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2015, it was in position 5/213, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-08-21:

  • Open Alex: 14
  • WoS: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-21:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 3 (PlumX).
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 3 - Good Health and Well-Being, with a probability of 75% according to the mBERT algorithm developed by Aurora University.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Garcia Martinez, Montserrat) .